摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(R)-N-{3-[3-fluoro-4-(1-benzyl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-2-oxooxazolidin-5-yl-methyl}azide | 371195-46-9

中文名称
——
中文别名
——
英文名称
(R)-N-{3-[3-fluoro-4-(1-benzyl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-2-oxooxazolidin-5-yl-methyl}azide
英文别名
(S)-N-[3-[3-fluoro-4-[1-benzyl-1,2,3,6-tetrahydropyridin-4-yl]phenyl]-2-oxooxazolidin-5-ylmethyl]azide;(5R)-3-(4-(1-Benzyl-1,2,5,6-tetrahydropyridin-4-yl)-3-fluorophenyl)-5-azidomethyl-oxazolidin-2-one;(5R)-5-(azidomethyl)-3-[4-(1-benzyl-3,6-dihydro-2H-pyridin-4-yl)-3-fluorophenyl]-1,3-oxazolidin-2-one
(R)-N-{3-[3-fluoro-4-(1-benzyl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-2-oxooxazolidin-5-yl-methyl}azide化学式
CAS
371195-46-9
化学式
C22H22FN5O2
mdl
——
分子量
407.447
InChiKey
NJVILFCBMMKFBN-IBGZPJMESA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.2
  • 重原子数:
    30
  • 可旋转键数:
    6
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.32
  • 拓扑面积:
    47.1
  • 氢给体数:
    0
  • 氢受体数:
    6

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Oxazolidinone derivatives with antibiotic activity
    申请人:——
    公开号:US20030216373A1
    公开(公告)日:2003-11-20
    Compounds of the formula (I), or a pharmaceutically acceptable salt, or an in-vivo-hydrolysable ester thereof, 1 wherein HET is an N-linked 5-membered heteroaryl ring, optionally substituted on a C atom by an oxo or thioxo group; and/or by 1 or 2 (1-4C)alkyl groups; and/or on an available nitrogen atom by (1-4C)alkyl; or HET is an N-linked 6-membered heteroaryl ring containing up to three nitrogen heteroatoms in total, optionally substituted on a C atom as above; Q is selected from, for example, Q1 2 R 2 and R 3 are independently hydrogen or fluoro; T is selected from a range of groups, for example, of formula (TC 5 ) 3 wherein Rc is, for example, R 13 CO—, R 13 SO 2 — or R 13 CS—; wherein R 13 is, for example, optionally substituted (1-10C)alkyl or R 14 C(O)O(1-6C)alkyl wherein R 14 is optionally substituted (1-10C)alkyl; are useful as antibacterial agents; and processes for their manufacture and pharmaceutical compositions containing them are described.
    公式(I)的化合物,或其药学上可接受的盐,或其体内水解酯,其中HET是一个N-连接的5-成员杂环芳基环,可选地在碳原子上被氧化或硫代氧基取代;和/或由1或2个(1-4C)烷基基团取代;和/或在一个可用的氮原子上由(1-4C)烷基基团取代;或者HET是一个N-连接的6-成员杂环芳基环,总共包含最多三个氮杂原子,可选地在碳原子上如上所述取代;Q是选自,例如,Q12R2和R3独立地是氢或氟;T是选自一系列基团,例如,如下式(TC5)3其中Rc是,例如,R13CO—,R13SO2—或R13CS—;其中R13是,例如,可选地取代的(1-10C)烷基或R14C(O)O(1-6C)烷基,其中R14是可选地取代的(1-10C)烷基;作为抗菌剂是有用的;并描述了它们的制备方法和含有它们的药物组合物。
  • [EN] OXAZOLIDINONE DERIVATIVES AS ANTIBACTERIAL AGENTS<br/>[FR] DERIVES D'OXAZOLIDINONE UTILISES EN TANT QU'AGENTS ANTIBACTERIENS
    申请人:ORCHID CHEMICALS & PHARM LTD
    公开号:WO2003097640A1
    公开(公告)日:2003-11-27
    The present invention provides novel compounds of the general formula (I), their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their hydrates, their solvates, their pharmaceutically acceptable salts and pharmaceutically acceptable compositions containing them. The present invention more particularly provides novel oxazolidinone derivatives of the general formula (I).
    本发明提供了一般式(I)的新化合物,它们的衍生物、类似物、互变异构体、立体异构体、多晶形态、水合物、溶剂物、药学上可接受的盐以及含有它们的药学上可接受的组合物。本发明更特别地提供了一般式(I)的新的噁唑烷酮衍生物。
  • [EN] OXAZOLIDINONE DERIVATIVES WITH ANTIBIOTIC ACTIVITY<br/>[FR] DERIVES D'OXAZOLIDINONE AYANT UNE ACTIVITE ANTIBIOTIQUE
    申请人:ASTRAZENECA AB
    公开号:WO2001081350A1
    公开(公告)日:2001-11-01
    Compounds of formula (I), or a pharmaceutically-acceptable salt, or an in-vivo-hydrolysable ester thereof, wherein HET is an N-linked 5-membered heteroaryl ring, optionally substituted on a C atom by an oxo or thioxo group; and/or by 1 or 2(1-4C) alkyl groups; and/or on an available nitrogen atom by (1-4C)alkyl; or HET is an N-linked 6-membered heteroaryl ring containing up to three nitrogen heteroatoms in total, optionally substituted on a C atom as above; Q is selected from, for example, (Q1), R?2 and R3¿ are independently hydrogen or fluoro; T is selected from a range of groups, for example, of formula (TC5), wherein Rc is, for example, R?13CO-, R13SO¿2- or R13CS-; wherein R13 is, for example, optionally substituted (1-10C)alkyl or R14C(O)O(1-6C)alkyl wherein R14 is optionally substituted (1-10C)alkyl; are useful as antibacterial agents; and processes for their manufacture and pharmaceutical compositions containing them are described.
    公式(I)的化合物,或其药学上可接受的盐,或其体内可水解的酯,其中HET是N-连接的5成员杂芳环,可选择在C原子上由氧或硫代氧基取代; 和/或由1或2(1-4C)烷基取代; 和/或在可用的氮原子上由(1-4C)烷基取代; 或者HET是N-连接的6成员杂芳环,总共包含最多三个氮杂原子,可选择在C原子上如上所述取代; Q是从(Q1)中选择,R?2和R3¿独立地为氢或氟; T是从一系列基团中选择,例如公式(TC5),其中Rc是例如R?13CO-,R13SO¿2-或R13CS-;其中R13例如是可选择取代的(1-10C)烷基或R14C(O)O(1-6C)烷基,其中R14是可选择取代的(1-10C)烷基; 适用于抗菌剂; 并描述了其制造过程和含有它们的制药组合物。
  • 3-Cyclyl-5-(nitrogen-containing 5-membered ring)methyl-oxazolidinone derivatives and their use as antibacterial agents
    申请人:Gravestock Barry Michael
    公开号:US20050119292A1
    公开(公告)日:2005-06-02
    Compounds of the formula (I), or a pharmaceutically-acceptable salt, or an in-vivo-hydrolysable ester thereof, wherein —N-HET is, for example, (Ic) or (If) wherein R1 is (1-4C)alkyl; Q is selected from, for example, Q1 wherein R 2 and R 3 are independently hydrogen or fluoro; T is selected from a range of groups, for example, wherein m is 0, 1 or 2; are useful as antibacterial agents; and processes for their manufacture and pharmaceutical compositions containing them are described.
    公式(I)的化合物,或其药学上可接受的盐,或其体内可水解的酯,其中- N-HET是(Ic)或(If),其中R1是(1-4C)烷基;Q从Q1中选择,其中R2和R3分别是氢或氟;T从一系列基团中选择,例如,其中m为0、1或2;这些化合物可用作抗菌剂;并描述了其制造方法和含有它们的药物组成物。
  • 3-cyclyl-5-(nitrogen-containing 5-membered ring)methyl-oxazolidinone derivatives and their use as antibacterial agents
    申请人:AstraZeneca AB
    公开号:US07473699B2
    公开(公告)日:2009-01-06
    Compounds of the formula (I), or a pharmaceutically-acceptable salt, or an in-vivo-hydrolysable ester thereof, wherein —N-HET is, for example, (Ic) or (If) wherein R1 is (1-4C)alkyl; Q is selected from, for example, Q1 wherein R2 and R3 are independently hydrogen or fluoro; T is selected from a range of groups, for example, wherein m is 0, 1 or 2; are useful as antibacterial agents; and processes for their manufacture and pharmaceutical compositions containing them are described.
    式(I)的化合物,或其药学上可接受的盐,或其体内可水解的酯,其中—N-HET例如为(Ic)或(If),其中R1为(1-4C)烷基;Q从以下中选择,例如Q1,其中R2和R3独立地为氢或氟;T从一系列基团中选择,例如其中m为0、1或2;这些化合物可用作抗菌剂;并描述了它们的制造过程和含有它们的制药组合物。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐